Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

The role of antigen expression by thymomas in myasthenia gravis (MG) is not clear. Previous reports of acetylcholine receptor (AChR) mRNA expression by the highly sensitive reverse transcription-polymerase chain reactions (RT-PCR) produced varying results. To try to clarify this issue, we first used...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Maclennan, C, Vincent, A, Marx, A, Willcox, N, Gilhus, N, Newsom-Davis, J, Beeson, D
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2008

Παρόμοια τεκμήρια

Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations.
ανά: Croxen, R, κ.ά.
Έκδοση: (2002)

Antibodies to AChRs in seronegative myasthenia gravis
ανά: Leite, M, κ.ά.
Έκδοση: (2006)

Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
ανά: Farrugia, M, κ.ά.
Έκδοση: (2007)

Congenital myasthenic syndrome patients due to AChR epsilon subunit mutations
ανά: Bonifati, D, κ.ά.
Έκδοση: (2004)

Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
ανά: Mygland, A, κ.ά.
Έκδοση: (2000)

End-plate gamma- and epsilon-subunit mRNA levels in AChR deficiency syndrome due to epsilon-subunit null mutations.
ανά: Croxen, R, κ.ά.
Έκδοση: (2001)

Splice-site mutations in the achr epsilon subunit gene associated with congenital myasthenic syndrome
ανά: Croxen, R, κ.ά.
Έκδοση: (2000)

Thymoma and paraneoplastic myasthenia gravis.
ανά: Marx, A, κ.ά.
Έκδοση: (2010)

AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands.
ανά: Faber, C, κ.ά.
Έκδοση: (2009)

Correlation between polymorphisms in the AChR gamma and delta subunit promoters and clinical phenotype in AChR deficiency patients
ανά: Bonifati, D, κ.ά.
Έκδοση: (2004)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
ανά: Vuslat Yilmaz, κ.ά.
Έκδοση: (2015-01-01)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
ανά: Lee, J, κ.ά.
Έκδοση: (2016)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
ανά: Rui Zhao, κ.ά.
Έκδοση: (2021-06-01)

Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis.
ανά: Buckley, C, κ.ά.
Έκδοση: (2001)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
ανά: Saxena, A, κ.ά.
Έκδοση: (2017)

Lack of association between acetylcholine receptor epsilon polymorphisms and early-onset myasthenia gravis.
ανά: Bonifati, D, κ.ά.
Έκδοση: (2004)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
ανά: Yu Cai, κ.ά.
Έκδοση: (2021-07-01)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
ανά: Deymeer, F, κ.ά.
Έκδοση: (2007)

The clinical outcome in AChR-positive generalized myasthenia gravis: A retrospective observational study
ανά: Pawan T Ojha, κ.ά.
Έκδοση: (2023-01-01)

Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
ανά: Gregory Kordas, κ.ά.
Έκδοση: (2014-01-01)

The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
ανά: Gizem A Kaya, κ.ά.
Έκδοση: (2014-01-01)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
ανά: Antonino Lupica, κ.ά.
Έκδοση: (2022-04-01)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients.
ανά: PLOS ONE Staff
Έκδοση: (2015-01-01)

Correction: direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
ανά: PLOS ONE Staff
Έκδοση: (2015-01-01)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
ανά: Chao Huang, κ.ά.
Έκδοση: (2022-07-01)

A cysteine residue close to the C-terminus of the E subunit is essential for surface acetylcholine receptor (AChR) expression: Implications for AChR deficiency syndrome
ανά: Ealing, J, κ.ά.
Έκδοση: (2002)

Selective silencing of pathogenic a subunit AChR mutant in dominant disorders
ανά: Abdelgany, A, κ.ά.
Έκδοση: (2004)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
ανά: Li‐Kai Tsai, κ.ά.
Έκδοση: (2021-06-01)

Clinical outcomes in AchR antibody-positive myasthenia gravis: Where does rituximab stand in the current times?
ανά: Megha Chetan Dhamne
Έκδοση: (2023-01-01)

Mutations in congenital myasthenic syndromes reveal an epsilon subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR.
ανά: Ealing, J, κ.ά.
Έκδοση: (2002)

Neuromyotonia and myasthenia gravis without thymoma.
ανά: Van Parijs, V, κ.ά.
Έκδοση: (2002)

Slow‐channel myasthenia due to novel mutation in M2 domain of AChR delta subunit
ανά: Xin‐Ming Shen, κ.ά.
Έκδοση: (2019-10-01)

Ocular myasthenia gravis and thymoma
ανά: Victor Alegre-Ituarte, κ.ά.
Έκδοση: (2022-09-01)

AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.
ανά: Plested, C, κ.ά.
Έκδοση: (2002)

Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain
ανά: Elena Cortés-Vicente, κ.ά.
Έκδοση: (2025-01-01)

Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
ανά: Nairong Xie, κ.ά.
Έκδοση: (2025-01-01)

Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.
ανά: Webster, R, κ.ά.
Έκδοση: (2004)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
ανά: Eleonora Lekova, κ.ά.
Έκδοση: (2022-09-01)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
ανά: Yuping Chen, κ.ά.
Έκδοση: (2022-05-01)

Structural abnormalities of the AChR caused by mutations underlying congenital myasthenic syndromes.
ανά: Beeson, D, κ.ά.
Έκδοση: (2003)